Changing the treatment paradigm in myelodysplastic syndromes. - Wikidata - awgldk - TriplyDB

Changing the treatment paradigm in myelodysplastic syndromes.

Changing the treatment paradigm in myelodysplastic syndromes.

http://www.wikidata.org/entity/Q37277994

about

Health care utilization and mortality among elderly patients with myelodysplastic syndromes.Iron overload in myelodysplastic syndromes: diagnosis and management.

P2860

Q33392602-53A83676-18FF-4D03-BC31-3EC8A06853A4 Q37686048-83907CC0-0713-44FE-A7ED-623ECD8758B6

P2860

Changing the treatment paradigm in myelodysplastic syndromes.

http://www.wikidata.org/entity/Q37277994

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changing the treatment paradigm in myelodysplastic syndromes.

@en

Changing the treatment paradigm in myelodysplastic syndromes.

@nl

type

label

Changing the treatment paradigm in myelodysplastic syndromes.

@en

Changing the treatment paradigm in myelodysplastic syndromes.

@nl

prefLabel

Changing the treatment paradigm in myelodysplastic syndromes.

@en

Changing the treatment paradigm in myelodysplastic syndromes.

@nl

P1433

Q37277994-501A6116-7751-4F08-BDC1-743E98E2B5CC

P1476

Q37277994-902E0592-CDBE-4F8E-B7B5-C9331877EEE7

P2093

Q37277994-19FF5AF1-F1BF-4347-B457-DF5B90638561

Q37277994-1ECDF406-698E-4ACF-8B17-F59FF5B79050

P2860

Q37277994-052858C7-8B22-41E4-83C0-AA8BBAE04D56

Q37277994-112A8C7B-AADF-48EB-BF1B-5EB0B3BAFE4A

Q37277994-1544E8E0-D3A7-4766-BFBA-E1A953519768

Q37277994-17EDEC7E-711F-4E54-8EB0-C918CCBC4B00

Q37277994-232E058B-6934-4819-BC45-68A3ACF90043

Q37277994-2D165DEB-FA10-4901-8B50-E053B0CBB864

Q37277994-3251D567-C937-4F8D-8F21-D7F2DB7A6CC2

Q37277994-351C8502-381E-4734-9A71-E6ABC9837A85

Q37277994-3C2F28D6-B93A-4609-A3B9-7E239C6A1893

Q37277994-3E0F19FA-4DE2-4EDC-8E01-996F6B6D76C7

P304

Q37277994-A5A226D5-C192-4538-A7A5-594481CB63BC

P31

Q37277994-141E8BDB-FC1B-44EA-B45F-D9CE5E55C412

Q37277994-5de30135-9620-4939-b0cc-715d0ff81803

P356

Q37277994-D7C54B24-8426-45BB-AC33-A8999A1B4384

P478

Q37277994-58526E9B-E814-48C4-9D63-766187091FA7

P577

Q37277994-6E83C581-2DBD-4C27-BAF2-3BE1C7827A87

P698

Q37277994-9D433BA7-EACD-4482-ACE1-122D272E8C14

P356

107327480801504S03

P1433

P1476

Changing the treatment paradigm in myelodysplastic syndromes.

@en

P2093

Ghulam J Mufti

http://www.w3.org/2001/XMLSchema#string

Tara L Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Cytogenetic features in myelodysplastic syndromes

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

The role of lenalidomide in the management of myelodysplasia with del 5q.

Myelodysplasia.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Bone marrow transplantation for myelodysplasia.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

P304

14-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107327480801504S03

http://www.w3.org/2001/XMLSchema#string

P478

15 Suppl

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18813206

http://www.w3.org/2001/XMLSchema#string